National Health (Immunisation Program – Designated Vaccines) Variation Determination 2016 (No. 1) (Cth)
National Health (Immunisation Program – Designated Vaccines) Variation Determination 2016 (No. 1)[1]
National Health Act 1953
I, Masha Somi, Delegate of the Minister for Health, make this Determination under subsections 9B (2) and (5) of the National Health Act 1953.
Dated 29 April 2016
Dr Masha Somi
Assistant Secretary
Immunisation Branch
Office of Health Protection
Department of Health
Delegate of the Minister for Health
Name of Determination
This Determination is the National Health (Immunisation Program – Designated Vaccines) Variation Determination 2016 (No. 1).
Commencement
(a) Items 1 to 3 of the Schedule commence on the day after registration.
(b) Item 4 of the Schedule commences on 1 July 2016.
3 Authority
These Rules are made under subsections 9B (2) and (5) of the National Health Act 1953.
Variation of National Health (Immunisation Program – Designated Vaccines) Determination 2014 (No. 1)
The Schedule varies the National Health (Immunisation Program – Designated Vaccines) Determination 2014 (No. 1).
Schedule
[1] Subsection 7(8)
Omit, substitute
(8) For items 207A and 207B of Schedule 1, a designated vaccine mentioned in those items may be provided to:
(a) a person who is at least 65 years; or
(b) an Aboriginal or Torres Strait Islander person who is:(i) aged at least 3 years but less than 5 years; or
(ii) 15 years or older; or
(c) a person who is at least 3 years who:
(i) has cardiac disease including cyanotic congenital heart disease, coronary artery disease and congestive heart failure; or
(ii) has a chronic respiratory condition including suppurative lung disease, bronchiectasis, cystic fibrosis, chronic obstructive pulmonary disease, chronic emphysema and severe asthma; or
(iii) has another chronic illness requiring regular medical follow-up or hospitalisation in the preceding year, including diabetes mellitus, chronic metabolic diseases, chronic renal failure, haemoglobinopathies and impaired immunity (including drug-induced immune impairment); or
(iv) has a chronic neurological condition, including multiple sclerosis, spinal cord injuries, seizure disorders or other neuromuscular disorders; or
(v) has impaired immunity, including HIV infection; or
(d) a person who is at least 3 years but less than 11 years and is receiving long-term aspirin therapy; or
(e) a woman who is pregnant.
[2] After item 207A in Schedule 1, Part 2
Insert
| 207B | Vaccine Influenza Circumstances Vaccine may be provided in the circumstances set out in subsection 7 (8). | FluQuadri | Injection (0.5mL) | For children 3 years and older, but less than 9 years – 2 doses at least 1 month apart for the first vaccination and 1 dose per calendar year after that. For persons 9 years and above, 1 dose per calendar year. |
[3] Item 218 in Schedule 1, Part 2 for Cervarix
Omit the item, substitute
| 219 | Vaccine Human papillomavirus (HPV) Circumstances Vaccine may be provided to: a female who is at least 12 years old but less than 14 years of age. | Cervarix | Injection (0.5mL) | Each of the following: (a) HPV 16 L1 protein - 20μg; (b) HPV 18 L1 protein - 20μg | 2 doses |
[4] After item 217 in Schedule 1, Part 2
Insert
| 217A | Vaccine Herpes zoster (shingles) Circumstances Vaccine may be provided to an immunocompetent person who: (a) is 70 years of age; or (b) is at least 71 and less than 80 years of age and presents for vaccination before 1 November 2021. | Zostavax | Injection (0.65mL) | Each Oka/Merck strain of VZV – 19,400 PFU | 1 dose |
[1]Note
All legislative instruments and compilations are registered on the Federal Register of Legislation kept under the Legislation Act 2003. See
0
0
0